Salt intake linked to gut inflammation in Crohn's patients
NCT ID NCT07169123
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study looks at how eating salt affects gut health in people with Crohn's disease. Researchers will track salt intake and measure gut inflammation in 300 participants. The goal is to understand if a high-salt diet worsens symptoms and to improve dietary advice for managing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better, personalized diet recommendations for people with Crohn's disease to help manage their condition.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McMaster University
RECRUITINGHamilton, Ontario, L8N 3Z5, Canada
-
McMaster University Medical Centre
NOT_YET_RECRUITINGHamilton, Ontario, L8S 4L8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Green gut check: can ultrasound slash the carbon cost of IBD testing?
- Real-World surgery study aims to improve fistula care
- New Dye-Free colonoscopy could make cancer screening easier for IBD patients
- Hidden mineral shortage: new study targets magnesium in gut patients
- Real-World study tracks how IBD patients choose between IV and injectable vedolizumab